Pharmakologische Rückfallprophylaxe bei Alkoholabhängigkeit

• Literatur

• John U, Hapke U, Rumpf HJ, Hill A, Dilling H. Prävalenz und Sekundärprävention von Alkoholmissbrauch und -abhängigkeit in der medizinischen Versorgung.. Baden-Baden: Nomos 1996
• Mann K. Neuroscience of Psychoactive Substance Use and Dependence.. Addiction 2004; 99 (10): 1361
• Bühringer G, Augustin R, Bergmann E. et al. Alkoholkonsum und alkoholbezogene Störungen in Deutschland.. Baden-Baden: Nomos 2000
• Kiefer F, Mann K. New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependence.. Eur J Pharmacol 2005; 526: 163-171
• Verheul R, van den Brink W, Geerlings P. A three-pathway psychobiological model of craving for alcohol.. Alcohol Alcohol 1999; 34: 197-222
• Cunningham C, Noble D. Conditioned activation induced by ethanol: role in sensitization and conditioned place preference.. Pharmacol Biochem Behav 1992; 43: 307-313
• Spanagel R, Pendyala G, Abarca C. et al. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption.. Nat Med 2005; 11: 35-42
• Sellers EM, Higgins GA, Sobell MB. 5-HT and alcohol abuse.. Trends Pharmacol Sci 1992; 13: 69-75
• Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence.. Arch Gen Psychiatry 1996; 53: 673-680
• Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis.. Alcohol Clin Exp Res 2004; 28: 51-63
• Ansoms C, Deckers F, Lehert P, Pelc I, Potgieter A. An open study with acamprosate in Belgium and Luxemburg: results on sociodemographics, supportive treatment and outcome.. Eur Addict Res 2000; 6: 132-140
• Anton RF, O'Malley SS, Ciraulo DA. et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.. JAMA 2006; 295: 2003-2017
• Mann K, Kiefer F. Acamprosate in the treatment of alcoholism: mechanisms and perspectives.. Future Neurology 2006; 1: 277-284
• Kiefer F, Mann K. Pharmacotherapy and behavioral intervention for alcohol dependence.. JAMA 2006; 296: 1727-1728
• Kiefer F, Wiedemann K. Neuroendocrine pathways of addictive behaviour.. Addict Biol 2004; 9: 205-212
• Froehlich JC, Harts J, Lumeng L, Li TK. Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference.. Pharmacol Biochem Behav 1990; 35: 385-390
• Anton RF. Alcohol craving - a renaissance.. Alcohol Clin Exp Res 1999; 23: 1289-95
• Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence.. Arch Gen Psychiatry 1992; 49: 876-880
• O'Malley SS, Jaffe AJ, Chang G, Schottenfeld R, Meyer RE, Rounsaville B. Naltrexon and Coping Skills Therapy for Alcohol Dependence.. Arch Gen Psychiatry 1992; 49: 881-887
• Gastpar M, Bonnet U, Boning J. Lack of Efficacy of Naltrexone in the Prevention of Alcohol Relapse: Results From a German Multicenter Study.. J Clin Psychopharmacol 2002; 22: 592-598
• Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence.. N Engl J Med 2001; 345: 1734-1739
• Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials.. Int J Neuropsychopharmacol 2005; 8 (2): 267-280
• Ehrenreich H. In: Mann KF (ed) Neue Therapieansätze bei Alkoholproblemen.. Lengerich,Pabst: 2002: 145-160
• Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study.. Alcohol Clin Exp Res 1998; 22: 573-579
• De Sousa A, de Sousa A. Naltrexon vs disulfiram. A one year follow up of alcohol dependence treatment.. Alcohol Alcohol 2004; 39: 528-531
• De Sousa A, De Sousa A. An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence.. Alcohol Alcohol 2005; 40: 545-548
• Berglund M, Thelander S, Salaspuro M, Franck I, Andreasson S, Ojehagen A. Treatment of alcohol abuse: an evidence based review.. Alcohol Clin Exp Res 2003; 27: 1645-1656
• Mutschler J, Diehl A, Vollmert C, Herre H, Kiefer F. Renaissance von Disulfiram in der aktuellen Suchtmedizin.. 2007 (submitted)
• Olbrich R, Olbrich R. Disulfiram (Antabus) in der Suchtbehandlung.. Sucht 2007; 53 (2): 72-81
• Fritze J. Psychopharmakaverordnungen: Ergebnisse und Kommentare zum Arzneiverordnungsreport 2004.. http://www.dgppn.de/stellungnahmen/Arzneiverordnungsreport-2004-Fritze.pdf
• Mann K. Project PREDICT.. http//www.bw-suchtweb.de 2005
• Kiefer F, Helwig H, Tarnaske T, Otte C, Jahn H, Wiedemann K. Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.. Eur Addict Res 2005; 11: 83-91
• Berglund M. A better widget? Three lessons for improving addiction treatment from a meta-analytical study.. Addiction 2005; 100: 742-750
• Kiefer F, Jahn H, Tarnaske T. et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study.. Arch Gen Psychiatry 2003; 60: 92-99
• Mason BJ, Goodman AM, Dixon RM. et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone.. Neuropsychopharmacology 2002; 27: 596-606
• Kiefer F, Wiedemann K. Combined therapy: what does acamprosate and naltrexone combination tell us?. Alcohol Alcohol 2004; 39: 542-547
• Oslin DW, Berrettini W, Kranzler HR. et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.. Neuropsychopharmacology 2003; 28: 1546-1552
• Gelernter J, Gueorguieva R, Kranzler HR. et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.. Alcohol Clin Exp Res 2007; 31: 555-563